STADA’s Frank Staud takes on additional role as head of global government affairs

16 January 2026

Effective January1, 2026, STADA Arzneimitel’s (SAZ: Xetra) global head of communications, Frank Staud, is additionally assuming global responsibility for STADA’s global government affairs, the German generics and consumer healthcare major announced today.

“Due to STADA's strong growth in all regions and changing geopolitical structures, whereby the importance of individual countries is increasing, we see new opportunities for STADA to realize country-specific solutions and growth opportunities in the healthcare sector with national governments,” explained STADA chief executive Peter Goldschmidt, adding: “This is in line with STADA's overarching strategy of responding locally to the needs of patients and healthcare professionals, and finding individual solutions for different healthcare systems.”

STADA's overarching goal is to be prepared for legislative risks and opportunities, and to ensure that the company's interests are reflected in political decisions. This applies to all areas in which STADA operates: consumer healthcare, specialty (innovations) and generics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Generics